NDA 022110 · Apotex
Vibativ
Telavancin Hydrochloride · Intravenous
NovelLast checked: Nov 20, 2026Latest source record: Jul 7, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Sep 11, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
5 Phase 3, 1 recruiting
FAERS reports
120
91 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN HABP/VABP PATIENTS WITH PRE-EXISTING MODERATE OR SEVERE RENAL IMPAIRMENT, NEPHROTOXICITY, POTENTIAL ADVERSE DEVELOPMENTAL OUTCOMES Patients with pre-existing moderate/severe renal impairment (CrCl ≤ 50 mL/min) who were treated with VIBATIV for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) had increased mortality observed versus vancomycin. Use of VIBATIV in patients with pre-existing moderate/severe renal impairment (CrCl ≤ 50 mL/min) should be considered only when the anticipated benefit to the patient outweighs the potential risk [see Warnings and Precautions ( 5.1 , 8.4 )]. Nephrotoxicity: New onset or worsening renal impairment has occurred. Monitor renal function in all patients [see Warnings and Precautions ( 5.3 )] . Embryofetal Toxicity: VIBATIV may cause fetal harm. In animal reproduction studies,...
What it is approved for
From the label in effect Dec 19, 2025.
VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs VIBATIV should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. 1.1 Complicated Skin and Skin Structure Infections VIBATIV is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus) , or Enterococcus faecalis (vancomycinsusceptible isolates only). 1.2 HABP/VABP VIBATIV is indicated for the treatment of adult patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Staphylococcus aureus (both methicillin-susceptible and -resistant isolates). VIBATIV should be reserved for use when alternative treatments are not suitable. 1.3 Usage Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative organisms. Appropriate specimens for bacteriological examination should be obtained in order to...
Mechanism: Telavancin is an antibacterial drug [ see Clinical Pharmacology ( 12.4 ) ].
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 6, 2016 Supplement 12 · Efficacy LetterLabel
- Sep 11, 2009 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
2 products under this application
- VIBATIV · TELAVANCIN HYDROCHLORIDE EQ 250MG BASE/VIAL · POWDER, INTRAVENOUS · Discontinued
- VIBATIV · TELAVANCIN HYDROCHLORIDE EQ 750MG BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Telavancin" as an intervention, any sponsor and status, largest first.
- Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus AureusPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00107978 · 1,035 participants · Start Feb 2005 · Primary completion May 2006
Drug: Telavancin; Vancomycin · For: Staphylococcal Skin Infection
Sites: New Orleans, Louisiana
- Comparison of Telavancin and Vancomycin for Complicated Skin and Skin Structure Infections With a Focus on Methicillin-resistant Staphylococcus AureusPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00091819 · 862 participants · Start Jan 2005 · Primary completion Jun 2006
Drug: Telavancin; Vancomycin · For: Staphylococcal Skin Infection
Sites: National City, California
- Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus AureusPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00124020 · 771 participants · Start Jan 2005 · Primary completion May 2007
Drug: Telavancin; Vancomycin · For: Bacterial Pneumonia
Sites: Tel HaShomer, Israel
- Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus AureusPivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00107952 · 761 participants · Start Feb 2005 · Primary completion Jul 2007
Drug: Telavancin; Vancomycin · For: Bacterial Pneumonia
Sites: Springfield, Massachusetts
- Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)Pivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00077675 · 201 participants · Start Feb 2004 · Primary completion Sep 2004
Drug: Telavancin; vancomycin or antistaphylococcal penicillin · For: Infections, Gram-positive Bacterial
Sites: National City, California
- Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)Pivotal-lookingCompleted
Cumberland PharmaceuticalsIndustry
NCT00061633 · 169 participants · Start Jun 2003 · Primary completion Jan 2004
Drug: Telavancin; Vancomycin or antistaphylococcal penicillin · For: Infections, Gram-Positive Bacterial; Abscess; Burns and 3 more
Sites: Chula Vista, California
- A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia TrialPivotal-lookingTerminated
Cumberland PharmaceuticalsIndustry
NCT02208063 · 121 participants · Start Dec 2014 · Primary completion Apr 12, 2018
Drug: Telavancin; Vancomycin and 3 more · For: Bacteremia
Sites: Columbus, Ohio
Cumberland PharmaceuticalsIndustry
NCT00062647 · 60 participants · Start Aug 2003 · Primary completion Aug 2006
Drug: Telavancin; Vancomycin, nafcillin, oxacillin, or cloxacillin · For: Gram-Positive Bacterial Infections
Sites: Marietta, Georgia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use19
- renal failure acute15
- blood creatinine increased12
- nausea12
- chills9
- thrombocytopenia7
- diarrhoea6
- dyspnoea6
- leukopenia6
- renal failure6
- vomiting6
- acute kidney injury5
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2009 | 2 |
| 2010 | 33 |
| 2011 | 45 |
| 2012 | 5 |
| 2014 | 4 |
| 2016 | 1 |
| 2018 | 23 |
| 2019 | 4 |
| 2025 | 1 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vibativ (Telavancin HCl)
2024 spending
$553K
Beneficiaries
33
137 claims
Per beneficiary
$16,770
$33.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $628,663 |
| 2022 | $618,855 |
| 2023 | $781,599 |
| 2024 | $553,402 |
Part B: Vibativ (Telavancin HCL) · HCPCS J3095
2024 spending
$1.1M
Beneficiaries
138
1,362 claims
Per beneficiary
$7,729
2024 ASP limit $7.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,871,453 |
| 2021 | $1,353,073 |
| 2022 | $1,223,977 |
| 2023 | $1,683,613 |
| 2024 | $1,066,665 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
Polyzos KA, Mavros MN, Vardakas KZ, et al. · PLoS One 2012 · Meta-Analysis, Systematic Review
- Gateways to clinical trials.
Bayés M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2004 · Clinical Trial
- Population pharmacokinetics of telavancin in healthy subjects and patients with infections.
Samara E, Shaw JP, Barriere SL, et al. · Antimicrob Agents Chemother 2012 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E, Lalani T, Corey GR, et al. · Clin Infect Dis 2011 · Comparative Study, Randomized Controlled Trial
- Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.
El Hassani M, Caissy JA, Marsot A · Clin Pharmacokinet 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Apotex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.